Alphatec Secures Exclusive Rights to OsteoAdapt® Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ATEC?
Source: Newsfilter
Alphatec Holdings Inc (ATEC) saw a significant decline of 19.38% as it crossed below its 5-day SMA, reflecting investor concerns following recent news.
The company has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft. This partnership is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure. OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its potential to revolutionize the bone regeneration market.
Despite the recent stock decline, the strategic partnership positions Alphatec to capitalize on a significant market opportunity in the U.S. spine surgery market, which exceeds $10 billion annually. The ongoing clinical trials and the expected commercialization of OsteoAdapt could drive future revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATEC
Wall Street analysts forecast ATEC stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 11.000
Low
20.00
Averages
24.33
High
28.00
Current: 11.000
Low
20.00
Averages
24.33
High
28.00
About ATEC
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alphatec Executive Sells 116,367 Shares Amid Market Fluctuations
- Executive Stock Sale: Craig Hunsaker, EVP of Alphatec Holdings, executed an open-market sale of 116,367 shares valued at approximately $1.44 million, reflecting a larger-than-typical transaction size compared to the recent median of 80,438 shares across six prior sales.
- Ownership Proportion Change: This sale reduced Hunsaker's direct holdings from about 1.84 million to 1.73 million shares, representing a 6.32% decrease, yet his remaining stake is valued at approximately $22.21 million, indicating sustained confidence in the company's future.
- Tax Plan Execution: A portion of the shares sold, specifically 33,602, was executed under a Rule 10b5-1 plan adopted on March 5, 2025, to cover tax obligations related to vested restricted stock units, aligning with Hunsaker's established periodic trading pattern.
- Company Financial Status: Despite Alphatec's revenue reaching $764.2 million in 2025, up from $611.6 million the previous year, the company reported a net loss of $143.4 million, highlighting the dual challenges and opportunities it faces in the market.
See More
Alphatec Executive Sells 116,367 Shares
- Executive Share Sale: Craig Hunsaker, EVP of Alphatec Holdings, sold 116,367 shares across two transactions on March 6 and 9, 2026, totaling approximately $1.44 million at an average price of $12.38 per share, reducing his direct holdings to 1.73 million shares, indicating a cautious outlook on the company's future.
- Tax Obligation Coverage: Part of the sale was to cover tax withholding obligations, and with Hunsaker retaining over 1.7 million shares, it suggests he is not in a hurry to divest, reflecting confidence in the company's long-term prospects.
- Sales Growth Forecast: Alphatec's sales reached $764.2 million in 2025, up from $611.6 million the previous year, with a forecasted increase to $890 million in 2026; despite still being unprofitable, the net loss decreased from $162.1 million in 2024 to $143.4 million last year.
- Market Reaction and Investment Advice: Although Alphatec's stock has significantly declined from its 52-week high of $23.29, its current price-to-sales ratio of two is lower than in recent months, potentially presenting a buying opportunity, yet analysts have not included it in their top stock picks, warranting careful investment consideration.
See More
Alphatec CFO Sells 79,789 Shares for $986,000
- Insider Selling Details: John Todd Koning, CFO of Alphatec Holdings, sold 79,789 shares on March 13, 2026, for approximately $986,000, representing 11.7% of his direct holdings, reducing his ownership to 600,721 shares, indicating a typical liquidity event rather than a signal of company performance.
- Transaction Context: The sale was executed under a 10b5-1 plan primarily to address tax liabilities from RSU vesting, and with the stock rising only about 9% over the past year, there is little evidence of opportunistic selling, suggesting the company's fundamentals remain strong.
- Financial Performance Highlights: In 2025, Alphatec reported total revenues of $764 million, marking a solid 25% year-over-year increase, with adjusted EBITDA reaching $93 million and margins climbing to 12%, reflecting success in increasing procedural volumes and adoption by new surgeons, despite still reporting GAAP losses that have narrowed significantly.
- Future Growth Outlook: Management forecasts revenue of around $890 million for 2026, indicating continued double-digit growth, which underscores the company's strategic focus on expanding its differentiated product portfolio and enhancing procedural outcomes, while the insider selling should be viewed as background noise for long-term investors focused on execution and cash flow generation.
See More
Alphatec CFO Sells Nearly 80,000 Shares in Direct Transaction
- Insider Stock Sale: Alphatec Holdings CFO John Todd Koning sold 79,789 shares for approximately $986,000, indicating a liquidity need within the company, as this transaction represented 11.7% of his direct holdings, still within historical norms.
- Company Financial Overview: As of now, Alphatec has a market capitalization of $1.7 billion and annual revenue of $764 million, despite reporting a net loss of $143.36 million, the company achieved a 25% revenue growth in 2025, showcasing its market potential and growth capability.
- Future Growth Expectations: Management forecasts revenue of around $890 million for 2026, indicating continued double-digit growth potential in the spine care sector, with improved cash flow conditions despite GAAP losses, ending the year with approximately $161 million in cash reserves.
- Strategic Execution Focus: This stock sale is primarily linked to tax obligations, reflecting the CFO's liquidity needs rather than a signal of the company's underlying performance, prompting investors to focus on the company's ability to maintain surgeon adoption and convert revenue growth into consistent cash flow.
See More
Alphatec (ATEC.US) Officer Plans to Sell $3.21 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Scott Lish intends to sell 260,540 shares of Alphatec (ATEC) common stock on March 13, with a total market value of approximately $3.21 million.
Reduction in Shareholding: Scott Lish has reduced his shareholding in Alphatec by 19,900 shares since December 16, 2025, with a total value of around $389.96K.
See More
Alphatec Holdings Shows Strong Growth Potential
- Strong Financial Performance: Alphatec Holdings, Inc. reported a preliminary total revenue increase of approximately 25% for fiscal year 2025, with surgical revenue growth of 26%, surgical volume growth of 24%, and a 2% increase in average revenue per procedure, indicating robust market performance and growth potential.
- Market Expectation Adjustment: TD Cowen lowered the price target for Alphatec from $27 to $20 while maintaining a Buy rating, suggesting that the market has not fully recognized the company's growth vectors, indicating potential upside in future estimates.
- Positive Outlook: The company expects total revenue of $890 million for fiscal year 2026, demonstrating ongoing growth momentum and market confidence, further solidifying its position in the spinal fusion technology sector.
- Competitive Environment Analysis: While Alphatec shows strong growth potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diversified view of investment opportunities in the market.
See More
Alphatec Executive Sells 116,367 Shares Amid Market Fluctuations
- Executive Stock Sale: Craig Hunsaker, EVP of Alphatec Holdings, executed an open-market sale of 116,367 shares valued at approximately $1.44 million, reflecting a larger-than-typical transaction size compared to the recent median of 80,438 shares across six prior sales.
- Ownership Proportion Change: This sale reduced Hunsaker's direct holdings from about 1.84 million to 1.73 million shares, representing a 6.32% decrease, yet his remaining stake is valued at approximately $22.21 million, indicating sustained confidence in the company's future.
- Tax Plan Execution: A portion of the shares sold, specifically 33,602, was executed under a Rule 10b5-1 plan adopted on March 5, 2025, to cover tax obligations related to vested restricted stock units, aligning with Hunsaker's established periodic trading pattern.
- Company Financial Status: Despite Alphatec's revenue reaching $764.2 million in 2025, up from $611.6 million the previous year, the company reported a net loss of $143.4 million, highlighting the dual challenges and opportunities it faces in the market.
See More
Alphatec Executive Sells 116,367 Shares
- Executive Share Sale: Craig Hunsaker, EVP of Alphatec Holdings, sold 116,367 shares across two transactions on March 6 and 9, 2026, totaling approximately $1.44 million at an average price of $12.38 per share, reducing his direct holdings to 1.73 million shares, indicating a cautious outlook on the company's future.
- Tax Obligation Coverage: Part of the sale was to cover tax withholding obligations, and with Hunsaker retaining over 1.7 million shares, it suggests he is not in a hurry to divest, reflecting confidence in the company's long-term prospects.
- Sales Growth Forecast: Alphatec's sales reached $764.2 million in 2025, up from $611.6 million the previous year, with a forecasted increase to $890 million in 2026; despite still being unprofitable, the net loss decreased from $162.1 million in 2024 to $143.4 million last year.
- Market Reaction and Investment Advice: Although Alphatec's stock has significantly declined from its 52-week high of $23.29, its current price-to-sales ratio of two is lower than in recent months, potentially presenting a buying opportunity, yet analysts have not included it in their top stock picks, warranting careful investment consideration.
See More
Alphatec CFO Sells 79,789 Shares for $986,000
- Insider Selling Details: John Todd Koning, CFO of Alphatec Holdings, sold 79,789 shares on March 13, 2026, for approximately $986,000, representing 11.7% of his direct holdings, reducing his ownership to 600,721 shares, indicating a typical liquidity event rather than a signal of company performance.
- Transaction Context: The sale was executed under a 10b5-1 plan primarily to address tax liabilities from RSU vesting, and with the stock rising only about 9% over the past year, there is little evidence of opportunistic selling, suggesting the company's fundamentals remain strong.
- Financial Performance Highlights: In 2025, Alphatec reported total revenues of $764 million, marking a solid 25% year-over-year increase, with adjusted EBITDA reaching $93 million and margins climbing to 12%, reflecting success in increasing procedural volumes and adoption by new surgeons, despite still reporting GAAP losses that have narrowed significantly.
- Future Growth Outlook: Management forecasts revenue of around $890 million for 2026, indicating continued double-digit growth, which underscores the company's strategic focus on expanding its differentiated product portfolio and enhancing procedural outcomes, while the insider selling should be viewed as background noise for long-term investors focused on execution and cash flow generation.
See More
Alphatec CFO Sells Nearly 80,000 Shares in Direct Transaction
- Insider Stock Sale: Alphatec Holdings CFO John Todd Koning sold 79,789 shares for approximately $986,000, indicating a liquidity need within the company, as this transaction represented 11.7% of his direct holdings, still within historical norms.
- Company Financial Overview: As of now, Alphatec has a market capitalization of $1.7 billion and annual revenue of $764 million, despite reporting a net loss of $143.36 million, the company achieved a 25% revenue growth in 2025, showcasing its market potential and growth capability.
- Future Growth Expectations: Management forecasts revenue of around $890 million for 2026, indicating continued double-digit growth potential in the spine care sector, with improved cash flow conditions despite GAAP losses, ending the year with approximately $161 million in cash reserves.
- Strategic Execution Focus: This stock sale is primarily linked to tax obligations, reflecting the CFO's liquidity needs rather than a signal of the company's underlying performance, prompting investors to focus on the company's ability to maintain surgeon adoption and convert revenue growth into consistent cash flow.
See More
Alphatec (ATEC.US) Officer Plans to Sell $3.21 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Scott Lish intends to sell 260,540 shares of Alphatec (ATEC) common stock on March 13, with a total market value of approximately $3.21 million.
Reduction in Shareholding: Scott Lish has reduced his shareholding in Alphatec by 19,900 shares since December 16, 2025, with a total value of around $389.96K.
See More
Alphatec Holdings Shows Strong Growth Potential
- Strong Financial Performance: Alphatec Holdings, Inc. reported a preliminary total revenue increase of approximately 25% for fiscal year 2025, with surgical revenue growth of 26%, surgical volume growth of 24%, and a 2% increase in average revenue per procedure, indicating robust market performance and growth potential.
- Market Expectation Adjustment: TD Cowen lowered the price target for Alphatec from $27 to $20 while maintaining a Buy rating, suggesting that the market has not fully recognized the company's growth vectors, indicating potential upside in future estimates.
- Positive Outlook: The company expects total revenue of $890 million for fiscal year 2026, demonstrating ongoing growth momentum and market confidence, further solidifying its position in the spinal fusion technology sector.
- Competitive Environment Analysis: While Alphatec shows strong growth potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diversified view of investment opportunities in the market.
See More
